1887

Abstract

Hypervirulent strains, most notably BI/NAP1/027, have been increasingly emerging in Western countries as local epidemics. We performed a prospective multicentre observational study from December 2011 to May 2012 to identify recent incidences of toxigenic culture-confirmed hospital-onset infections (CDI) and their associated clinical characteristics in South Korea. Patients suspected of having been suffering from CDI more than 48 h after admission and aged ≥20 years were prospectively enrolled and provided loose stool specimens. Toxigenic culture (anaerobic culture+toxin A/B/binary gene PCR) and PCR ribotyping were performed in one central laboratory. We enrolled 98 toxigenic culture-confirmed CDI-infected patients and 250 toxigenic culture-negative participants from three hospitals. The incidence of toxigenic culture-confirmed hospital-onset CDI cases was 2.7 per 10 000 patient-days. The percentage of severe CDI cases was relatively low at only 3.1 %. UK ribotype 018 was the predominant type (48.1 %). There were no hypervirulent BI/NAP1/027 isolates identified. The independent risk factors for toxigenic culture-confirmed hospital-onset CDI were invasive procedure (odds ratio (OR) 7.3,  = 0.003) and past CDI history within 3 months (OR 28.5,  = 0.003). In conclusion, the incidence and severity of CDI in our study were not higher than reported in Western countries.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.070672-0
2014-11-01
2020-09-24
Loading full text...

Full text loading...

/deliver/fulltext/jmm/63/11/1542.html?itemId=/content/journal/jmm/10.1099/jmm.0.070672-0&mimeType=html&fmt=ahah

References

  1. Alonso R., Martín A., Peláez T., Marín M., Rodríguez-Creixéms M., Bouza E. 2005; Toxigenic status of Clostridium difficile in a large Spanish teaching hospital. J Med Microbiol 54:159–162 [CrossRef][PubMed]
    [Google Scholar]
  2. Anand A., Bashey B., Mir T., Glatt A. E. 1994; Epidemiology, clinical manifestations, and outcome of Clostridium difficile-associated diarrhea. Am J Gastroenterol 89:519–523[PubMed]
    [Google Scholar]
  3. Barbut F., Richard A., Hamadi K., Chomette V., Burghoffer B., Petit J. C. 2000; Epidemiology of recurrences or reinfections of Clostridium difficile-associated diarrhea. J Clin Microbiol 38:2386–2388[PubMed]
    [Google Scholar]
  4. Barbut F., Decré D., Lalande V., Burghoffer B., Noussair L., Gigandon A., Espinasse F., Raskine L., Robert J.& other authors ( 2005; Clinical features of Clostridium difficile-associated diarrhoea due to binary toxin (actin-specific ADP-ribosyltransferase)-producing strains. J Med Microbiol 54:181–185 [CrossRef][PubMed]
    [Google Scholar]
  5. Bartlett J. G. 1994; Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis 18:Suppl. 4S265–S272 [CrossRef][PubMed]
    [Google Scholar]
  6. Bartlett J. G., Chang T. W., Gurwith M., Gorbach S. L., Onderdonk A. B. 1978; Antibiotic-associated pseudomembranous colitis due to toxin-producing clostridia. N Engl J Med 298:531–534 [CrossRef][PubMed]
    [Google Scholar]
  7. Bauer M. P., Notermans D. W., van Benthem B. H., Brazier J. S., Wilcox M. H., Rupnik M., Monnet D. L., van Dissel J. T., Kuijper E. J.ECDIS Study Group 2011; Clostridium difficile infection in Europe: a hospital-based survey. Lancet 377:63–73 [CrossRef][PubMed]
    [Google Scholar]
  8. Bignardi G. E. 1998; Risk factors for Clostridium difficile infection. J Hosp Infect 40:1–15 [CrossRef][PubMed]
    [Google Scholar]
  9. Byun T. J., Han D. S., Ahn S. B., Cho H. S., Kim T. Y., Eun C. S., Jeon Y. C., Sohn J. H., Kang J. O. 2009; [Clinical characteristics and changing epidemiology of Clostridium difficile-associated disease (CDAD)]. Korean J Gastroenterol 54:13–19 (in Korean) [CrossRef][PubMed]
    [Google Scholar]
  10. Clements A. C., Magalhães R. J., Tatem A. J., Paterson D. L., Riley T. V. 2010; Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread. Lancet Infect Dis 10:395–404 [CrossRef][PubMed]
    [Google Scholar]
  11. Crobach M. J., Dekkers O. M., Wilcox M. H., Kuijper E. J. 2009; European Society of Clinical Microbiology and Infectious Diseases (ESCMID): data review and recommendations for diagnosing Clostridium difficile-infection (CDI). Clin Microbiol Infect 15:1053–1066 [CrossRef][PubMed]
    [Google Scholar]
  12. Delmée M., Van Broeck J., Simon A., Janssens M., Avesani V. 2005; Laboratory diagnosis of Clostridium difficile-associated diarrhoea: a plea for culture. J Med Microbiol 54:187–191 [CrossRef][PubMed]
    [Google Scholar]
  13. Dubberke E. R., Butler A. M., Yokoe D. S., Mayer J., Hota B., Mangino J. E., Khan Y. M., Popovich K. J., Fraser V. J. 2010; Multicenter study of Clostridium difficile infection rates from 2000 to 2006. Infect Control Hosp Epidemiol 31:1030–1037 [CrossRef][PubMed]
    [Google Scholar]
  14. Freeman J., Bauer M. P., Baines S. D., Corver J., Fawley W. N., Goorhuis B., Kuijper E. J., Wilcox M. H. 2010; The changing epidemiology of Clostridium difficile infections. Clin Microbiol Rev 23:529–549 [CrossRef][PubMed]
    [Google Scholar]
  15. Gilca R., Hubert B., Fortin E., Gaulin C., Dionne M. 2010; Epidemiological patterns and hospital characteristics associated with increased incidence of Clostridium difficile infection in Quebec, Canada, 1998-2006. Infect Control Hosp Epidemiol 31:939–947 [CrossRef][PubMed]
    [Google Scholar]
  16. Goorhuis A., Bakker D., Corver J., Debast S. B., Harmanus C., Notermans D. W., Bergwerff A. A., Dekker F. W., Kuijper E. J. 2008; Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 47:1162–1170 [CrossRef][PubMed]
    [Google Scholar]
  17. Gravel D., Miller M., Simor A., Taylor G., Gardam M., McGeer A., Hutchinson J., Moore D., Kelly S.& other authors ( 2009; Health care-associated Clostridium difficile infection in adults admitted to acute care hospitals in Canada: a Canadian Nosocomial Infection Surveillance Program Study. Clin Infect Dis 48:568–576 [CrossRef][PubMed]
    [Google Scholar]
  18. Henrich T. J., Krakower D., Bitton A., Yokoe D. S. 2009; Clinical risk factors for severe Clostridium difficile-associated disease. Emerg Infect Dis 15:415–422 [CrossRef][PubMed]
    [Google Scholar]
  19. Kato H., Kato N., Watanabe K., Iwai N., Nakamura H., Yamamoto T., Suzuki K., Kim S. M., Chong Y., Wasito E. B. 1998; Identification of toxin A-negative, toxin B-positive Clostridium difficile by PCR. J Clin Microbiol 36:2178–2182[PubMed]
    [Google Scholar]
  20. Kim B. N. 2005; Compliance with an infectious disease specialist’s advisory consultations on targeted antibiotic usage. J Infect Chemother 11:84–88 [CrossRef][PubMed]
    [Google Scholar]
  21. Kim H., Jeong S. H., Roh K. H., Hong S. G., Kim J. W., Shin M. G., Kim M. N., Shin H. B., Uh Y.& other authors ( 2010; Investigation of toxin gene diversity, molecular epidemiology, and antimicrobial resistance of Clostridium difficile isolated from 12 hospitals in South Korea. Korean J Lab Med 30:491–497 [CrossRef][PubMed]
    [Google Scholar]
  22. Kim H., Lee Y., Moon H. W., Lim C. S., Lee K., Chong Y. 2011; Emergence of Clostridium difficile ribotype 027 in Korea. Korean J Lab Med 31:191–196 [CrossRef][PubMed]
    [Google Scholar]
  23. Kim J., Kang J. O., Kim H., Seo M. R., Choi T. Y., Pai H., Kuijper E. J., Sanders I., Fawley W. 2013a; Epidemiology of Clostridium difficile infections in a tertiary-care hospital in Korea. Clin Microbiol Infect 19:521–527 [CrossRef][PubMed]
    [Google Scholar]
  24. Kim Y. S., Han D. S., Kim Y. H., Kim W. H., Kim J. S., Kim H. S., Kim H. S., Park Y. S., Song H. J.& other authors ( 2013b; Incidence and clinical features of Clostridium difficile infection in Korea: a nationwide study. Epidemiol Infect 141:189–194 [CrossRef][PubMed]
    [Google Scholar]
  25. Kuehne S. A., Cartman S. T., Heap J. T., Kelly M. L., Cockayne A., Minton N. P. 2010; The role of toxin A and toxin B in Clostridium difficile infection. Nature 467:711–713 [CrossRef][PubMed]
    [Google Scholar]
  26. Kyne L., Warny M., Qamar A., Kelly C. P. 2000; Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 342:390–397 [CrossRef][PubMed]
    [Google Scholar]
  27. Kyne L., Hamel M. B., Polavaram R., Kelly C. P. 2002; Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis 34:346–353 [CrossRef][PubMed]
    [Google Scholar]
  28. Lee K., Park K. H., Jeong S. H., Lim H. S., Shin J. H., Yong D., Ha G.-Y., Chong Y.KONSAR 2006; Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance. Yonsei Med J 47:43–54 [CrossRef][PubMed]
    [Google Scholar]
  29. Lee Y. J., Choi M. G., Lim C. H., Jung W. R., Cho H. S., Sung H. Y., Nam K. W., Chang J. H., Cho Y. K. other authors 2010; [Change of Clostridium difficile colitis during recent 10 years in Korea]. Korean J Gastroenterol 55:169–174 (in Korean) [CrossRef][PubMed]
    [Google Scholar]
  30. Lee K., Kim M. N., Kim J. S., Hong H. L., Kang J. O., Shin J. H., Park Y. J., Yong D., Jeong S. H., Chong Y.KONSAR Group 2011; Further increases in carbapenem-, amikacin-, and fluoroquinolone-resistant isolates of Acinetobacter spp. and P. aeruginosa in Korea: KONSAR study 2009. Yonsei Med J 52:793–802 [CrossRef][PubMed]
    [Google Scholar]
  31. Lessa F. C., Gould C. V., McDonald L. C. 2012; Current status of Clostridium difficile infection epidemiology. Clin Infect Dis 55:Suppl 2S65–S70 [CrossRef][PubMed]
    [Google Scholar]
  32. Lo Vecchio A., Zacur G. M. 2012; Clostridium difficile infection: an update on epidemiology, risk factors, and therapeutic options. Curr Opin Gastroenterol 28:1–9 [CrossRef][PubMed]
    [Google Scholar]
  33. O’Connor J. R., Johnson S., Gerding D. N. 2009; Clostridium difficile infection caused by the epidemic BI/NAP1/027 strain. Gastroenterology 136:1913–1924 [CrossRef][PubMed]
    [Google Scholar]
  34. Patriarchi F., Rolla M., Maccioni F., Menichella A., Scacchi C., Ambrosini A., Costantino A., Quattrucci S. 2011; Clostridium difficile-related pancolitis in lung-transplanted patients with cystic fibrosis. Clin Transplant 25:E46–E51 [CrossRef][PubMed]
    [Google Scholar]
  35. Pépin J., Valiquette L., Alary M. E., Villemure P., Pelletier A., Forget K., Pépin K., Chouinard D. 2004; Clostridium difficile-associated diarrhea in a region of Quebec from 1991 to 2003: a changing pattern of disease severity. CMAJ 171:466–472 [CrossRef][PubMed]
    [Google Scholar]
  36. Peterson L. R., Manson R. U., Paule S. M., Hacek D. M., Robicsek A., Thomson R. B. Jr, Kaul K. L. 2007; Detection of toxigenic Clostridium difficile in stool samples by real-time polymerase chain reaction for the diagnosis of C. difficile-associated diarrhea. Clin Infect Dis 45:1152–1160 [CrossRef][PubMed]
    [Google Scholar]
  37. Ricciardi R., Rothenberger D. A., Madoff R. D., Baxter N. N. 2007; Increasing prevalence and severity of Clostridium difficile colitis in hospitalized patients in the United States. Arch Surg 142:624–631, discussion 631 [CrossRef][PubMed]
    [Google Scholar]
  38. Riley T. V., Brazier J. S., Hassan H., Williams K., Phillips K. D. 1987; Comparison of alcohol shock enrichment and selective enrichment for the isolation of Clostridium difficile. Epidemiol Infect 99:355–359 [CrossRef][PubMed]
    [Google Scholar]
  39. Rubin M. S., Bodenstein L. E., Kent K. C. 1995; Severe Clostridium difficile colitis. Dis Colon Rectum 38:350–354 [CrossRef][PubMed]
    [Google Scholar]
  40. Safdar N. 2012; Clostridium difficile: the emerging epidemic. Mayo Clin Proc 87:1037–1039 [CrossRef][PubMed]
    [Google Scholar]
  41. Shin B. M., Kuak E. Y., Yoo H. M., Kim E. C., Lee K., Kang J. O., Whang D. H., Shin J. H. 2008a; Multicentre study of the prevalence of toxigenic Clostridium difficile in Korea: results of a retrospective study 2000–2005. J Med Microbiol 57:697–701 [CrossRef][PubMed]
    [Google Scholar]
  42. Shin B. M., Kuak E. Y., Yoo S. J., Shin W. C., Yoo H. M. 2008b; Emerging toxin AB+ variant strain of Clostridium difficile responsible for pseudomembranous colitis at a tertiary care hospital in Korea. Diagn Microbiol Infect Dis 60:333–337 [CrossRef][PubMed]
    [Google Scholar]
  43. Shin S., Kim M., Kim M., Lim H., Kim H., Lee K., Chong Y. 2012; Evaluation of the Xpert Clostridium difficile assay for the diagnosis of Clostridium difficile infection. Annals Lab Med 32:355–358 [CrossRef][PubMed]
    [Google Scholar]
  44. Stubbs S. L., Brazier J. S., O’Neill G. L., Duerden B. I. 1999; PCR targeted to the 16S-23S rRNA gene intergenic spacer region of Clostridium difficile and construction of a library consisting of 116 different PCR ribotypes. J Clin Microbiol 37:461–463[PubMed]
    [Google Scholar]
  45. Stubbs S., Rupnik M., Gibert M., Brazier J., Duerden B., Popoff M. 2000; Production of actin-specific ADP-ribosyltransferase (binary toxin) by strains of Clostridium difficile. FEMS Microbiol Lett 186:307–312 [CrossRef][PubMed]
    [Google Scholar]
  46. Tae C. H., Jung S. A., Song H. J., Kim S. E., Choi H. J., Lee M., Hwang Y., Kim H., Lee K. 2009; The first case of antibiotic-associated colitis by Clostridium difficile PCR ribotype 027 in Korea. J Korean Med Sci 24:520–524 [CrossRef][PubMed]
    [Google Scholar]
  47. Terhes G., Urbán E., Sóki J., Hamid K. A., Nagy E. 2004; Community-acquired Clostridium difficile diarrhea caused by binary toxin, toxin A, and toxin B gene-positive isolates in Hungary. J Clin Microbiol 42:4316–4318 [CrossRef][PubMed]
    [Google Scholar]
  48. Zar F. A., Bakkanagari S. R., Moorthi K. M., Davis M. B. 2007; A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 45:302–307 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.070672-0
Loading
/content/journal/jmm/10.1099/jmm.0.070672-0
Loading

Data & Media loading...

Most cited this month Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error